Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?

Medical Hypotheses

Volumn 76, Issue 1, 2011, Pages 105-109

  Kalambokis, Georgios ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYTOKINE; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE; NORFLOXACIN; RIFAXIMIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL TRANSLOCATION; BLOOD CELL COUNT; CYTOKINE RELEASE; CYTOPENIA; DISEASE SEVERITY; ENDOTOXEMIA; ERYTHROCYTE COUNT; HEMATOPOIESIS; HUMAN; HYPERSPLENISM; LEUKOCYTE COUNT; LEUKOPENIA; LIVER BIOPSY; LIVER CIRRHOSIS; LONG TERM CARE; PATHOGENESIS; PHAGOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTI-BACTERIAL AGENTS; ENDOTOXEMIA; HUMANS; LIVER CIRRHOSIS; MODELS, THEORETICAL; THROMBOCYTOPENIA;

BACTERIA (MICROORGANISMS);

EID: 78650175565     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.08.043     Document Type: Article

References (57)

1. Quamar A.A., Grace N.D., Groszmann R.J., et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009, 7:689-695.
2. Afdhal N., McHutchinson J., Brown R., et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008, 48:1000-1007.
3. Toghill P.J., Green S. Splenic influences on the blood in chronic liver disease. Q J Med 1979, 48:613-625.
4. Shah S.H., Haves P.C., Allan P.L., Nicoll J., Finlayson N.D. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol 1996, 91:2580-2583.
5. McCormick P.A., Murphy K.M. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000, 14:1009-1031.
6. Ohashi T., Fujiwara K. Hematologic abnormalities in liver disease. Nippon Naika Gakkai Zasshi 1982, 71:1677-1681.
7. Petz L.D. Hematologic aspects of liver disease. Curr Opin Gastroenterol 1989, 5:372-377.
8. Bruno C.M., Neri S., Sciacca C., et al. Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver disease. World J Gastroenterol 2004, 10:1353-1356.
9. Siciliano M., Tomasello D., Milani A., Ricerca B.M., Storti S., Rossi L. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 1995, 22:1132-1135.
10. Korolko I.U.R., Sarycheva T.G., Kotelnikov V.M., Kozinets G.I., Zherebtsof L.A. Anemic syndrome in chronic hepatitis and liver cirrhosis. Klin Med 1993, 71:45-48.
11. Ohki I., Dan K., Kuriya S., Nomura T. A study on the mechanism of anemia and leukopenia in liver cirrhosis. Jpn J Med 1988, 27:155-159.
12. Koike Y., Yoneyama A., Shirai J., et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998, 79:1106-1110.
13. Witters P., Freson K., Verlype C., et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008, 27:1017-1029.
14. Panasiuk A., Zak J., Kasprzycka E., Janicka K., Prokopowicz D. Blood platelet and monocyte activations and relation to stages of liver cirrhosis. World J Gastroenterol 2005, 11:2754-2758.
15. Amitrano L., Guardascione M.A., Brancaccio V., Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002, 22:83-96.
16. Kusaba N., Kumashiro R., Ogata H., Sata M., Tanikawa K. In vitro study of neutrophil apoptosis in liver cirrhosis. Intern Med 1998, 37:11-17.
17. Cirera I., Elizalde J.I., Pique J.M., et al. Anemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension. Dig Dis Sci 1997, 42:1697-1702.
18. Garcia-Tsao G. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18:353-372.
19. Lumsden A.B., Henderson J.M., Kutner M.H. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral blood in patients with cirrhosis. Hepatology 1988, 8:232-236.
20. Tilg H., Wilmer A., Vogel W., et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-274.
21. Moncada .S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
22. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102:783-788.
23. Genesca J., Gonzalez A., Torregosa M., Mujal A., Segura R. High levels of endotoxin antibodies contribute to hyperglobulinemia of cirrhotic patients. Am J Gastroenterol 1998, 93:664-665.
24. Holdstock G., Ershler W.B., Krawitt E.L. Demonstration of non-specific B-cell stimulation in patients with cirrhosis. Gut 1982, 23:724-728.
25. Richard C.A.H., Gudewicz P.W., Loegering D.J. IgG-coated erythrocytes augment the lipopolysaccharide-stimulated increase in serum tumor necrosis factor-α. Am J Physiol 1999, 276:R171-177.
26. McGrath K.M., Stuart J.J., Richards F. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinemic states. Br J Haematol 1979, 42:585-591.
27. Violi F., Ferri D., Basili S., et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995, 109:531-539.
28. Itoh H., Cicala C., Douglas G.J., Page C.P. Platelet accumulation induced by bacterial endotoxin in rats. Thromb Res 1996, 83:405-419.
29. Aslam R., Speck E.R., Kim M., et al. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 2006, 107:637-641.
30. Zarychanski R., Houston D.S. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?. CMAJ 2008, 179:333-337.
31. Weiss G., Goodnough L.T. Anaemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
32. De Maria R., Testa U., Luchetti L., et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999, 93:796-803.
33. Schooley J.C., Kullgren B., Allison A.C. Inhibition by interleukin-1 on the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anemias. Br J Haematol 1987, 67:11-17.
34. Jelkmann W., Pagel H., Wolff M., Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1991, 50:301-308.
35. Laftah A.H., Sharma N., Brookes M.J., et al. Tumor necrosis factor α causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J 2006, 397:61-67.
36. Moldawer L.L., Marano M.A., Wei H., et al. Cachectin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989, 3:1637-1643.
37. Sitter T., Bergner A., Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodynamic patients. Nephrol Dial Transplant 2000, 15:1207-1211.
38. Macdougall I.C., Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002, 17:39-43.
39. Davis D., Charles P.J., Potter A., Feldmann M., Maini R.N., Elliott M.J. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis factor α blockade. Br J Rheumatol 1997, 36:950-956.
40. Lee J.W., Beckham C., Michel B.R., Rosen H., Deeg H.J. HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway. Blood 1997, 90:217-225.
41. Crist S.A., Elzey B.D., Ludwig A.T., et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megacaryocytes and platelets. Exp Hematol 2004, 32:1073-1081.
42. Schwager I., Jungi T.W. Effect of human recombinant cytokines on the induction of macrophages procoagulant activity. Blood 1994, 83:152-160.
43. Endo Y., Nakamura M. The effect of lipopolysaccharide, interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse. Br J Pharmacol 1992, 105:613-619.
44. Salamone G., Giordano M., Trevani A.S., et al. Promotion of neutrophil apoptosis by TNF-α. J Immunol 2001, 166:3476-3483.
45. Suhasini M., Boss G.R., Pascual F.E., Pilz R.B. Nitric oxide releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression; correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression. Cell Growth Differ 1995, 6:1559.
46. Rafferty S.P., Domachowske J.B., Malech H.L. Inhibition of haemoglobin expression by heterologous production of nitric oxide synthase in the K562 erythroleukemic cell line. Blood 1996, 88:1070-1078.
47. Shami P.J., Weinberg J.B. Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34+ human bone narrow cells. Blood 1996, 87:977-982.
48. Schobersberger W., Hoffnamm G., Fandrey J. Nitric oxide donors suppress erythropoietin production in vitro. Pflugers Arch 1996, 432:980.
49. Schattner M., Pozner R.G., Engelberger I., et al. Effect of nitric oxide on megacaryocyte growth induced by thrombopoietin. J Lab Clin Med 2001, 137:261-269.
50. Sulowska Z., Majewska E., Klink M., Banasik M., Tchorzewski H. Flow cytometric evaluation of human neutrophil apoptosis during nitric oxide generation in vitro: the role of exogenous antioxidants. Mediators Inflamm 2005, 2:81-87.
51. Fortenberry J.D., Owens M.L., Brown M.R., et al. Exogenous nitric oxide enhances neutrophil cell death and DNA fragmentation. Am J Respir Cell Mol Biol 1998, 18:421-428.
52. Geffner J.R., Trevani A.S., de D'Elia I., Diament M., Klein D., Giordano M. Involvement of nitric oxide in the regulation of peripheral blood leukocyte counts. J Leukoc Biol 1995, 58:391-394.
53. Guarner C., Runyon B.A., Heck M., Young S., Sheikh M.Y. Effect of long-term trimethoprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis, and survival in cirrhotic rats. Dig Dis Sci 1999, 44:1957-1962.
54. Cirera I., Bauer T.M., Navasa M., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001, 34:32-37.
55. Albillos A., de la Hera A., Gonzalez M., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003, 37:208-217.
56. Rasaratnam B., Kaye D., Jennings G., Dudley F., Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. Ann Intern Med 2003, 139:186-193.
57. Vlachogiannakos J., Saveriadis A.S., Viazis N., et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-999.